The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom

The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom

Background: In response to COVID-19, the UK National Health Service (NHS) extended influenza vaccination in 50- to 64-year-olds from at-risk only to all in this age group for the 2020/21 season. The objective of this research is to determine the cost-effectiveness of continuing to vaccinate all with...

Full description

Bibliographic Details
Main Authors: Michele A. Kohli, Michael Maschio, Joaquin F. Mould-Quevedo, Mansoor Ashraf, Michael F. Drummond, Milton C. Weinstein
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Vaccines
Subjects:
influenza vaccine
cost-effectiveness
economic modeling
Online Access:https://www.mdpi.com/2076-393X/9/6/598

Similar Items

Similar Items